NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Emrock Corp Q2 FY27 Net Profit Rises to ₹1.78 Cr on Revenue of ₹3.03 Cr; Pharma Segment Drives Growth
Emrock Corporation reported standalone revenue from operations of ₹2.82 Cr and total revenue of ₹3.03 Cr for Q2 ended September 30, 2026, up sharply from ₹0.65 Cr in Q1 FY27. Net profit for the quarter came in at ₹1.78 Cr compared to ₹0.19 Cr in the preceding quarter, driven heavily by its newly reported Pharmaceutical segment, which contributed ₹2.42 Cr to segment revenue. The auditor included an emphasis of matter regarding 1.29 Cr convertible warrants still pending conversion and valuation uncertainties in real estate TDR inventory.
உச்சம் நம்பிக்கை
என்ன மாறியதுEmrock approved its Q2 FY27 unaudited financial results and approved an alteration/addition of the company's object clause.
ஏன் இது முக்கியம்The company's pivot into pharmaceuticals has substantially expanded its quarterly revenue base, which previously averaged under ₹1 Cr per quarter.
Q2 FY27 Total Revenue: Rs 303.06 LakhsQ2 FY27 Profit after Tax: Rs 177.76 LakhsPharma Segment Revenue: Rs 242.37 LakhsPending Warrants: 1,29,35,491 யூனிட்கள்Q2 வருவாய் vs TTM வருவாய்: ~151.5%
📅 குறுகிய காலம்Market reaction may be positive due to sequential revenue and profit expansion, though investors will closely assess the new pharma revenue line.
📈 நீண்ட காலம்Structural growth depends on scaling the solar and pharmaceutical divisions while successfully managing TDR inventory risks and capital dilution.
⚠ அபாய எச்சரிக்கைகள்
Dilution risk from 1.29 Cr warrants pending conversion
Auditor emphasis of matter on valuation and eligibility risks of TDR inventory
High P/E multiple valuation context
👀 கவனிக்க வேண்டியவை
Track the sustainability of the newly introduced pharmaceutical segment's revenues and margins, as well as the potential equity dilution from pending warrant conversions expiring within 18 months of their May 2025 allotment.
Emrock Corporation's Board approved the conversion of 74,35,491 warrants into equity shares of face value ₹10 each at an issue price of ₹11 per share. The company received the final 75% tranche aggregating to ₹6.13 crore (at ₹8.25 per warrant) from 10 allottees, including promoters. Following this allotment, the paid-up share capital increased from ₹21.32 crore (2.13 crore shares) to ₹28.76 crore (2.88 crore shares). With this transaction, all 2.35 crore warrants originally issued on May 10, 2025 have been fully converted.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe board approved the allotment of 74,35,491 equity shares following warrant conversion, concluding the conversion of the entire 2.35 crore warrant tranche issued in May 2025.
ஏன் இது முக்கியம்The company infuses ₹6.13 crore in fresh cash (significant against TTM revenue of ₹2 crore and net worth of ₹24 crore), while equity dilution expands paid-up capital by approximately 34.87%.
Shares Allotted: 74,35,491Issue Price per Warrant: Rs. 11/-Amount Received (75%): Rs. 6,13,42,800.75Post-Allotment Paid-up Capital: Rs. 28,75,54,910/-Amount Received vs Net Worth: ~25.5%
📅 குறுகிய காலம்Share count expands by 74.35 lakh shares, which may increase trading float once listing and trading approvals are granted.
📈 நீண்ட காலம்The additional ₹6.13 crore provides working capital and funding for business operations, though the expansion in share count results in equity dilution.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~34.9% on pre-allotment share base
Pending listing and trading approvals for recent share allotments
👀 கவனிக்க வேண்டியவை
Track the receipt of listing and trading approvals for the newly allotted shares on the stock exchange and observe how the capital infusion impacts upcoming quarterly balance sheets.
MD Jatinkumar Patel Acquires 13.20 Lakh Shares via Warrant Conversion for ₹1.45 Cr
Managing Director Jatinkumar Tulsibhai Patel acquired 13,20,000 equity shares of Emrock Corporation Ltd on October 30, 2026, via warrant conversion at an aggregate net purchase value of ₹1,45,20,000 (~₹11 per share). The allotment constitutes 6.19% of the expanded post-acquisition equity voting capital. Following the conversion, the acquirer's holding of voting shares increased from 38,95,972 shares (24.63%) to 52,15,972 shares (24.47% on an expanded post-acquisition capital base of 2,13,20,000 shares). The company's total voting capital increased from ₹15.82 crore to ₹21.32 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுMD Jatinkumar Patel converted warrants into 13.20 lakh equity shares, expanding the total voting share capital base to 2.13 crore shares.
ஏன் இது முக்கியம்Infuses ₹1.45 crore of equity capital into the company while expanding the equity base and altering percentage voting rights.
📅 குறுகிய காலம்Routine SAST disclosure following warrant conversion; minor equity dilution effect.
📈 நீண்ட காலம்Strengthens equity base, but ultimate value creation depends on capital deployment across planned solar and pharma diversifications.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from warrant conversions
High stock valuation multiples (P/E >400x) relative to small operating revenue base
👀 கவனிக்க வேண்டியவை
Track subsequent shareholding patterns to confirm final promoter group percentages and monitor use of proceeds from the warrant conversion.
Director & CFO Parth Patel Converts 13.2 Lakh Warrants to Equity for ₹1.45 Cr
Director & CFO Parth Tulsibhai Patel acquired 13,20,000 equity shares of Emrock Corporation Ltd via warrant conversion on October 30, 2026. The total net purchase value for the conversion was ₹1,45,20,000 (₹1.45 crore). Post-allotment, his direct voting rights increased from 24.63% to 24.47% on an expanded equity base (due to company-wide capital expansion to 2,13,20,000 shares), while holding 17,93,712 warrants remaining. This infusion brings ₹1.45 crore of equity funding into a company with TTM revenue of ₹2 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுPromoter-director Parth Patel converted 13.20 lakh warrants into equity shares, raising his equity share count to 52,15,972 shares.
ஏன் இது முக்கியம்Infuses ₹1.45 crore into the business (significant relative to TTM revenue of ₹2 crore), strengthening net worth while expanding the total equity base from 1.58 crore to 2.13 crore shares.
Shares acquired: 13,20,000Net purchase value: ₹1,45,20,000Equity capital pre-acquisition: ₹15,82,00,000Equity capital post-acquisition: ₹21,32,00,000Capital infusion vs TTM revenue: ~72.6%
📅 குறுகிய காலம்Neutral to mildly positive as insider capital infusion demonstrates promoter commitment, though equity dilution expands the share base.
📈 நீண்ட காலம்Provides equity funding for ongoing diversification into solar power and pharma, but ongoing warrant conversions continue to dilute EPS.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from warrant conversion expands share base
High valuation multiples relative to tiny revenue base (P/E above 400x on ₹2 Cr TTM revenue)
👀 கவனிக்க வேண்டியவை
Track the deployment of warrant conversion proceeds toward the company's stated solar and pharmaceutical diversification plans, along with subsequent quarterly dilution impacts.
Emrock Corporation has approved the allotment of 55,00,000 equity shares of face value ₹10 each at an issue price of ₹11 per share pursuant to warrant conversions. The company received ₹4,53,75,000, representing the remaining 75% balance of ₹8.25 per warrant from 8 allottees (including promoters). Consequent to this conversion, the paid-up equity share capital increases from ₹15.82 crore to ₹21.32 crore, representing an equity dilution of approximately 34.8%. Another 74,35,491 warrants remain pending conversion within the 18-month tenure.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoard approved the conversion of 55 lakh warrants into 55 lakh fully paid-up equity shares following receipt of ₹4.54 crore.
ஏன் இது முக்கியம்Provides ₹4.54 crore in growth and operational capital to the company, but expands the equity base by ~34.8%, creating significant EPS dilution.
Shares allotted: 55,00,000Issue price per share: Rs. 11/-Amount received (75%): Rs. 4,53,75,000Post-allotment paid-up capital: Rs. 21,32,00,000Warrants pending conversion: 7,435,491Funds received vs TTM revenue: ~227%
📅 குறுகிய காலம்Share count expands by ~34.8% once listed, which could create trading liquidity and potential overhang given the warrant price of ₹11 vs current market levels.
📈 நீண்ட காலம்Capital influx strengthens the balance sheet (net worth of ₹24 Cr previously), but substantial dilution will compress per-share earnings unless deployment into new segments yields rapid operating profits.
⚠ அபாய எச்சரிக்கைகள்
Substantial equity dilution of ~34.8% from this tranche alone
Further dilution risk from 74.35 lakh remaining pending warrants
Warrant conversion price (₹11) is deeply discounted relative to current market price (~₹255)
👀 கவனிக்க வேண்டியவை
Track listing and trading approvals for the newly allotted 55 lakh shares, as well as the conversion timeline and balance cash inflows for the remaining 74.35 lakh warrants.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Emrock Corp Secures 12 MW Solar PPAs with UGVCL; Annual Revenue Estimated at ₹6.38 Cr
Emrock Corporation has received confirmation from Uttar Gujarat Vij Company Limited (UGVCL) for 25-year Power Purchase Agreements (PPAs) covering 12 MW of solar power across three 4 MW projects. The projects carry a fixed tariff of ₹2.76 per unit, with estimated annual generation of 231 lakh units yielding approximately ₹6.38 crore in annual revenue. This represents over 300% of the company's TTM revenue of ₹2.06 crore, significantly expanding its renewable portfolio. With this win, Emrock's total confirmed solar capacity with UGVCL reaches 40 MW (1 operational, 6 under commissioning, and 3 newly confirmed).
உச்சம் நம்பிக்கை
என்ன மாறியதுEmrock received confirmed 25-year PPAs from UGVCL for 12 MW of solar capacity, taking total commitments with the utility to 40 MW.
ஏன் இது முக்கியம்The estimated annual revenue of ₹6.38 crore dwarfs the company's FY26 TTM revenue of ~₹2 crore, marking a decisive shift from real estate TDR facilitation into steady solar utility cash flows.
New solar capacity: 12 MWEstimated annual revenue: ₹637.56 லட்சம்PPA tariff: ₹2.76 per unitPPA tenure: 25 yearsTotal confirmed UGVCL capacity: 40 MWAnnual revenue vs TTM revenue: ~310%
📅 குறுகிய காலம்Positive sentiment driver given the substantial scale of the PPAs relative to the company's current low revenue base.
📈 நீண்ட காலம்Provides highly predictable long-term utility cash flows over 25 years, accelerating the company's strategic pivot into renewable power generation.
⚠ அபாய எச்சரிக்கைகள்
Execution timeline spans over 16 months (March 2028 commissioning)
Significant capex funding required relative to current net worth of ₹24 crore
Operational risks from solar generation intermittency and grid evacuation
👀 கவனிக்க வேண்டியவை
Monitor execution milestones for the 24 MW capacity due by May 2027 and these new 12 MW projects slated for March 2028, along with financing arrangements and capex funding.
Emrock Corporation Approves Q1 FY27 Standalone and Consolidated Financial Results
Emrock Corporation (formerly Vaghani Techno Build) approved its unaudited financial results for the quarter ended June 30, 2026, in a board meeting held on August 12, 2026. While the specific quarterly figures were not detailed in the cover letter, the company enters this period with a TTM revenue of just Rs 2 Cr and a high P/E of 540.0. The company is currently attempting to diversify from TDR facilitation into Solar Power and Pharmaceuticals. Investors should monitor the full financial tables for signs of revenue scaling in these new segments.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுThe company has completed and approved its financial reporting for the first quarter of the 2026-27 fiscal year.
ஏன் இது முக்கியம்For a micro-cap company with extremely low revenue (Rs 2 Cr) but a high market cap (Rs 616 Cr), quarterly results are the only way to track if the business pivot is actually gaining traction.
📅 குறுகிய காலம்The stock price may remain volatile as the market digests the specific growth trajectory shown in the full quarterly tables.
📈 நீண்ட காலம்The long-term outlook depends entirely on the successful execution of the diversification strategy into Solar and Pharma, as the core TDR business remains small and volatile.
⚠ அபாய எச்சரிக்கைகள்
Extremely high valuation (P/E 540)
Very low revenue base
Execution risk in new business segments
👀 கவனிக்க வேண்டியவை
Review the detailed P&L statement to verify if the new Solar and Pharma segments have commenced meaningful revenue generation to justify the current 540x P/E valuation.
Emrock Corp Acquires 51% Stake in New Solar Subsidiary for Rs 51,000
Emrock Corporation has acquired a 51% controlling stake in Emrock Renewable Private Limited, a newly incorporated entity (August 10, 2026). The acquisition was completed via a nominal cash subscription of Rs 51,000 for 5,100 shares at face value. This move formalizes the company's previously stated strategy to diversify from TDR facilitation into the high-growth renewable energy and EV charging sectors. While the initial investment is negligible relative to the company's Rs 24 Cr net worth, it marks the operational start of a new business vertical.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has established a new subsidiary to execute its diversification into the renewable energy sector, moving beyond its core TDR facilitation business.
ஏன் இது முக்கியம்This is a strategic pivot into a high-growth sector (Solar/EV) intended to mitigate the volatility and liquidity risks associated with the TDR (Real Estate) market.
Acquisition Cost: Rs 51,000Stake Acquired: 51%Target Paid-up Capital: Rs 1,00,000Acquisition vs Net Worth: 0.002%TTM வருவாய்: Rs 2 கோடி
📅 குறுகிய காலம்The market may react positively to the 'Renewable Energy' entry, though the immediate financial impact is negligible given the nominal investment amount.
📈 நீண்ட காலம்The success of this pivot depends on the company's ability to scale operations in a capital-intensive solar industry, which will require significantly more funding than the initial subscription.
⚠ அபாய எச்சரிக்கைகள்
Related-party transaction
Execution risk in a new, capital-intensive business line
High valuation (P/E 532) relative to current small revenue base
👀 கவனிக்க வேண்டியவை
Investors should monitor future disclosures regarding capital expenditure plans and project timelines for the new solar subsidiary to assess if it can meaningfully contribute to the current TTM revenue of Rs 2 Cr.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
